Qnasl generic
Qnasl is an aerosol, metered nasal drug owned by Teva Branded Pharm that contains beclomethasone dipropionate. It was first authorized for market use on March 23, 2012.
When will Qnasl generic be available?
The generic of Qnasl is expected to be released after October 21, 2031. This timeline is based on the expiry of the last patent. The patent, US10188811 titled 'Nasal spray device', is set to expire on that date.
Qnasl uses
Qnasl, containing the active ingredient beclomethasone dipropionate, is commonly used to treat nasal symptoms like congestion, itching, and sneezing caused by seasonal or year-round allergies.
Qnasl patent expiration
Qnasl has 2 patents, with the last one, titled 'Nasal spray device', expiring on October 21, 2031. This means Qnasl generic could potentially be available after that date. Below are the details of the patent: